Category Archives: Stem Cell Research

ResearchonIndia : Stem Cell Research in India 2012 For the complete report , visit us at : https://www.researchonindia.com/stem-cell-research-in-india-2012.html. By: indiamarketresearch … Continue reading →

Dallas, Texas (PRWEB) May 12, 2013 Analysis of global grant activity, scientific publication rates, and patent applications reveal that research activity involving mesenchymal stem cells increased 58% year-over-year from 2008 to 2009, and 112% from 2009 to 2010. Of most interest is that this rate of growth accelerated in 2011, making mesenchymal stem cells the fastest growing area of stem cell research. Mesenchymal stem cells (MSCs) are multipotent stem cells that can differentiate into a variety of cell types, including osteoblasts, chondrocytes, myocytes, adipocytes, beta-pancreatic islets cells, and potentially, neuronal cells. MSCs are of intense therapeutic interest because they represent a population of cells with the potential to treat a wide range of acute and degenerative diseases. Revealing Unique Strategic Opportunities & Unknown Competitive Advantages MSCs are advantageous over other stem cells types for several reasons. First, they avoid the ethical issues that surround embryonic stem cell research. Second, repeated studies have found that human MSCs are immuno-privileged, and therefore, represent an advantageous cell type for allogenic transplantation, reducing the risks of rejection and complications of transplantation. Recently, there have also been significant advances in the use of autologous MSCs to regenerate human tissues, including cartilage and meniscus, tendons, and … Continue reading →

PORT ST LUCIE, Fla., May 10, 2013 /PRNewswire/ --CleanPath Resources Corp (OTC Pink: CLNP) (www.re-load.biz) CleanPath Resources' newest research and development partner, BioSwan, Inc., just announced new research initiatives for its stem cell enhancement product NutraLoad. The next phase of research will take place in Europe and Asia and will be focused on NutraLoad's efficacy on targeted health issues. For the past 24 months BioSwan has been evaluating and validating the ability of NutraLoad to increase the level of stem cells in the circulatory system. These evaluations have been very promising and they have taken place with test patients in a medical facility located in Henderson, Nevada . The response to the product has been very positive creating a great deal of excitement for the official release of NutraLoad. BioSwan will release the results of its Nevada research to CLNP very soon. CleanPath's CEO Ken Lewis stated, "The positive results from the first round of testing have justified more in depth studies and has shown NutraLoad to be an excellent product well worth the wait." Ken Lewis 1-561-309-9876 kenlewis@re-load.biz Go here to see the original: CleanPath Resources Corp Announces Preliminary Research Report on New Stem Cell Enhancement Product NutraLoad™ … Continue reading →

Led by Dr. Peiyee Lee and Dr. Richard Gatti, researchers at the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA have used induced pluripotent stem (iPS) cells to advance disease-in-a-dish modeling of a rare genetic disorder, ataxia telangiectasia (A-T). Their discovery shows the positive effects of drugs that may lead to effective new treatments for the neurodegenerative disease. iPS cells are made from patients' skin cells, rather than from embryos, and they can become any type of cells, including brain cells, in the laboratory. The study appears online ahead of print in the journal Nature Communications. People with A-T begin life with neurological deficits that become devastating through progressive loss of function in a part of the brain called the cerebellum, which leads to severe difficulty with movement and coordination. A-T patients also suffer frequent infections due to their weakened immune systems and have an increased risk for cancer. The disease is caused by lost function in a gene, ATM, that normally repairs damaged DNA in the cells and preserves normal function. Developing a human neural cell model to understand A-T's neurodegenerative process and create a platform for testing new treatments was critical because … Continue reading →

Stem Cell Girl Growing Up Healthy 2 year old Hannah Warren was born without a windpipe but has become the first child to receive one transplanted to her that was derived from her own stem cel... By: TheLipTV … Continue reading →

Scottsdale, AZ (PRWEB) May 09, 2013 The new Arizona Pain Stem Cell Institute is beginning a research project involving stem cell injections. The study will evaluate the effectiveness of a regenerative medicine product clinically for back and neck pain along with pain in the shoulder, knee, hip and sacroiliac joint. Those interested should call (602) 507-6550. One of the main benefits of the study is that it is industry subsidized, therefore, the cost of the procedures is 40% less than the typical fees charged for the injections. The stem cell injection study is a non-randomized, prospective study looking at the effectiveness of stem cell injections into spinal joints for back and neck pain along with shoulder, hip, knee and the sacroiliac joints. The benefit of a non-randomized study is that all participants will receive the stem cell product. The product is an amniotic derived stem cell rich substance that also has a high concentrate of hyaluronic acid and growth factors. It is hypothesized that the stem cell portion of the injection will help repair and regenerate damaged tissue, but the hyaluronic acid and the growth factors may contribute to pain relief and tissue repair as well. Anecdotal reports of the … Continue reading →

CARLSBAD, CA--(Marketwired - May 9, 2013) - International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) a California-based biotechnology company developing novel stem cell based therapies announced today that it will host a conference call on Tuesday, May 14, 2013 to discuss its financial results for the three months ended March 31, 2013. Dr. Simon Craw, Executive Vice President and Mr. Jay Novak, Interim Chief Financial Officer of International Stem Cell will host the conference call. To attend the call, please use the dial in information below: Date: Tuesday, May 14, 2013 Time: 11:00 a.m. Eastern Time Conference Line (U.S.): 1-877-317-6776 International Dial-In: 1-412-317-6776 Conference ID: 10028807 Webcast: http://webcast.mzvaluemonitor.com/Cover.aspx?PlatformId=1293 Please dial in at least 10-minutes before the call to ensure timely participation. A playback of the call will be available until 11:00 a.m. ET on May 21. To listen, call 1-877-344-7529 within the United States or 1-412-317-0088 when calling internationally. Please use the replay pin number 10028807. About International Stem Cell Corporation International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells … Continue reading →

NEW YORK, May 8, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Cell Culture Market (Media, Sera, Reagents, Serum-Free Media, Albumin, Growth Factors & Cytokines, Instruments, Bioreactors, Roller Bottle Equipment, T-Flasks And Cryostorage Equipment) - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, http://www.reportlinker.com/p01172049/Cell-Culture-Market-Media-Sera-Reagents-Serum-Free-Media-Albumin-Growth-Factors--Cytokines-Instruments-Bioreactors-Roller-Bottle-Equipment-T-Flasks-And-Cryostorage-Equipment---Global-Industry-Analysis-Size-Share-Growth-Trends-And-Forecast.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=NoCategory The cell culture market is experiencing impressive growth globally because of the tremendous increase in demand for biopharmaceutical products. Since its introduction as an integral part of the life science industry, the cell culture market has experienced huge growth in terms of scope as well as adoption by end users. The rapid double-digit growth in biotechnology and biopharmaceutical industries is slated to be the major driving force for the growth of the cell culture market in the future. This report analyses the global market for cell culture by the two main types of products- consumables and instruments. Each of these segments has been further divided and analyzed by various product types offered by manufacturers. The market has also been segmented on the basis of end users into academics & research and commercial producers. All the above mentioned segments are analyzed on the basis of market size in … Continue reading →

NEW YORK, May 8, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Cell Culture: The Market for Media, Sera and Reagents, 5th Edition http://www.reportlinker.com/p01172034/Cell-Culture-The-Market-for-Media-Sera-and-Reagents-5th-Edition .html#utm_source=prnewswire&utm_medium=pr&utm_campaign=NoCategory The growth in biopharmaceuticals is creating an unprecedented increase in demand for cell culture products. Cell culture techniques have been used in biological sciences for more than 50 years; however, cell culture techniques have been applied to production systems for only about 26 years. The cell culture industry, which began in the late 1980s from the utilization of recombinant DNA technology and cell hybridization, is today a major underpinning of the biopharmaceutical market. The choice of cells to use in biopharmaceutical production depends on a number of factors, some technical and some economic. Bacteria and yeast, for instance, are relatively simple to grow. Each cell of a bacterium or yeast is an independent organism capable of its own metabolism. Yeasts and bacteria have fairly simple nutritional needs and grow well suspended in a liquid medium, as well as in large fermentors. This report is focused on cell culture used in the research and production of biopharmaceuticals. In the pharmaceutical industry, cell culture is a major foundation of … Continue reading →

NEWARK, Calif., May 7, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, announced today that it will release financial results for the first quarter ended March 31, 2013 after the market close on Thursday, May 9. In connection with this announcement, StemCells will host a conference call and webcast to discuss its results and an update on its business at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) the same day. Interested parties are invited to listen to the call over the Internet by accessing the Investors section of the Company's website at http://www.stemcellsinc.com. Webcast participants should allot extra time before the webcast begins to register and, if necessary, download and install audio software. An archived version of the webcast will also be available for replay on the Company's website beginning approximately two hours following the conclusion of the live call and continuing for a period of 30 days. About StemCells, Inc. StemCells, Inc. is engaged in the research, development, and commercialization of cell-based therapeutics and tools for use in stem cell-based research and drug discovery. The Company's lead … Continue reading →